Novo Nordisk stock has had a tough run over the past three years, yet the current valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both point to the shares trading at a discount to what the business may be worth.

• The share price has declined 35.6% over three years, which sets the backdrop for a value story rather than a momentum one.
• Approval and rapid uptake of the oral Wegovy pill can support long term cash flows, while intense GLP-1 competition and pricing pressure remain key risks to how much of that value ultimately reaches shareholders.
• Novo Nordisk screens as undervalued on 5 out of 6 valuation checks. This suggests the broader toolkit leans toward the stock being cheap rather than fully priced.

The issue now is whether Novo Nordisk’s current discount to intrinsic value offers enough compensation for the competitive, regulatory and execution risks around its GLP-1 franchise.

Is Novo Nordisk Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on projected cash flows to equity over two stages. For Novo Nordisk, the model starts from latest twelve month free cash flow of about DKK 48.2b and applies a growing cash flow profile over the coming decade, then tapers that growth in a terminal phase to reflect a more mature GLP-1 and diabetes business.

On these assumptions, the DCF model points to an estimated intrinsic value of about $96.43 per share. With the DCF implying the stock is 49.4% undervalued relative to the current share price, the cash flows being modeled support the idea that Novo Nordisk is priced below what its business may be worth. Recent pressure from Eli Lilly and other GLP-1 competitors has not changed the fact that the market price still sits well under this cash flow based estimate.

On this Discounted Cash Flow output, Novo Nordisk stock screens as undervalued compared with the value implied by its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 49.4%. Track this in your watchlist or portfolio, or discover 41 more high quality undervalued stocks.

Does Novo Nordisk Look Undervalued on Earnings?

P/E suits Novo Nordisk because earnings are still the main anchor for how investors look at large pharmaceutical stocks. Novo Nordisk currently trades at about 11.8x earnings, which is below the broader pharmaceuticals industry average of roughly 15.1x and well under the peer group average of 24.4x. That puts the stock on a comparatively low earnings multiple given its scale and GLP-1 exposure.

A tailored fair P/E ratio for Novo Nordisk, which adjusts for its margins, risk profile and size, sits around 23.5x. Set against the current 11.8x, this shows a sizeable gap between what investors are paying for each dollar of earnings today and what this framework suggests could be reasonable. For readers weighing GLP-1 competition, pricing pressure and regulatory risk, that spread indicates the market is already embedding a meaningful discount into Novo Nordisk’s earnings base.

On the P/E multiple, Novo Nordisk stock currently appears undervalued relative to what its earnings profile would typically justify.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Novo Nordisk pick up where the valuation checks stop by spelling out which future paths for growth, margins and earnings would make the current share price look high or low. Instead of a single output from a ratio or model, they describe the future that number relies on so you can monitor whether Novo Nordisk's actual progress stays in line. These Narratives sit on Simply Wall St's Community page.

One of the top community narratives on Novo Nordisk: 49% undervalued

"With durable economics, undervalued optionality, and long-duration growth potential, Novo Nordisk stands as a high-quality compounder available at a rare discount..."

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

For Novo Nordisk, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple work in the same direction, pointing to a stock that screens as undervalued rather than fully priced. The broader valuation checks also lean that way, which suggests the current price already reflects a fair amount of concern around GLP-1 competition, pricing and regulation.

What matters from here is whether Novo Nordisk can sustain the cash flow and earnings profile that underpin those models while defending its position in GLP-1. The key question for investors is whether the current discount represents mispricing or an accurate read on long term competitive and policy risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.